Prakt. lékáren. 2019; 15(2): 64-69 [Interní Med. 2019; 21(1): 14-19]

Osteoporosis – 2nd part, pharmacotherapy

Petra Matalová
Ústav farmakologie LF UP a FN Olomouc

Therapies of osteoporosis can be varied. Delivery of sufficient levels of calcium, synthesis of vitamin D in the skin and physical
activity are the most successful. When these nutrients are lacking, they need to be artificially added via use of medicaments.
The second most common method of therapy incorporates mainly bisphosphonates. Osteoanabolic therapy is also used. There
is a possibility of targetted therapy as well. The use of therapy has to be long. In these cases of prolonged therapies and often
asymptomatic diseases, the most important factor is the patient´s compliance and adherence.

Keywords: osteoporosis, treatment, calcium, vitamin D, bisphospohonates, denosumab

Published: June 20, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matalová P. Osteoporosis – 2nd part, pharmacotherapy. Praktické lékárenství. 2019;15(2):64-69.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Marek J a kolektiv autorů. Farmakoterapie vnitřních nemocí. Grada, 2010, s 417-425.
    2. Růžičková O. Možnosti léčby osteoporózy. Interní Med. 2017; 19 (5): 237-345. Go to original source...
    3. Dostupné z: www.nutridatabaze.cz, Ústav zemědělské ekonomiky a informací, online dne 17. 2. 2018
    4. Fojtík P, Urban O, Falt P, Novosad P. Výživa a sekundární osteoporóza. Interní Med. 2009; 11(12): 561-568.
    5. Kasper H. Výživa v medicíně a dietetika: Překlad 11. vydání, Praha: Grada 2015: 65 s.
    6. Wang H, Bua P, Capodice J. A comparative study of calcium absorption following a single serving administration of calcium carbonate powder versus calcium citrate tablets in healthy premenopausal women. Food Nutr Res. 2014; 58. Go to original source... Go to PubMed...
    7. Afshan S, Farah Musa AR et al. Persisting Hypocalcemia After Surgical Parathyroidectomy: The Differential Effectiveness of Calcium Citrate Versus Calcium Carbonate With Acid Suppression. Am J Med Sci. 2017; 353(1): 82-86. Go to original source... Go to PubMed...
    8. Bretšnajdrová M, Terrichová M, Závodný P. Kalcium a vitamin D u seniorů. Med. praxi 2011; 8(4): 163-166.
    9. Murray RK, Granner DK, Mayes PA, Rodwell VW. Harperova biochemie. Nakladatelství a vydavatelství H & H, Praha, 2002 s. 544-547.
    10. Vyskočil V. Antiresorpční léčiva v terapii osteoporózy a v redukci relativního rizika zlomenin. Remedia 2006; 16(4): 332-338.
    11. Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005; 37(4): 433-440. Go to original source... Go to PubMed...
    12. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017; 5(11): 898-907. Go to original source... Go to PubMed...
    13. Gennari L, Bilezikian JP. New and developing pharmacotherapy for osteoporosis in men. Expert Opin Pharmacother. 2018; 19(3): 253-264. Go to original source... Go to PubMed...
    14. Black DM, Schwartz AV, Ensrud KE et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296(24): 2927-2938. Go to original source... Go to PubMed...
    15. Cummings SR, Ettinger B, Delmas PD et al. The effects of tibolone in older postmenopasal women. N Engl J Med 2008; 359: 697-708. Go to original source... Go to PubMed...
    16. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice N Engl J Med. 2003; 348(7): 618-629. Go to original source... Go to PubMed...
    17. Skácelová S. Denosumab. Remedia 2011; 21: 230-237.
    18. Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765. Go to original source... Go to PubMed...
    19. Broulík P. Dvojí účinek parathormonu na kostní tkáň. Interní Med. 2008; 10 (5): 224-226.
    20. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19): 1434-1441. Go to original source... Go to PubMed...
    21. Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.N Engl J Med. 2007; 357(20): 2028-2039. Go to original source... Go to PubMed...
    22. Miller PD, Hattersley G, Riis BJ et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2006; 16;316(7): 722-733. Go to original source... Go to PubMed...
    23. Saag KG, Petersen J, Brandi ML et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377: 1417-1427. Go to original source... Go to PubMed...
    24. Liu Y, Cao Y, Zhang S et al. Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric. 2018; 9: 1-7. Go to original source... Go to PubMed...
    25. Hannon RA, Clack G, Rimmer M et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res. 2010; 25(3): 463-471. Go to original source... Go to PubMed...
    26. Vytrisalova M, Touskova T, Ladova K et al. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter. Climacteric. 2015; 18(4): 608-616. Go to original source... Go to PubMed...
    27. Boonen S, Ferrari S, Miller PD et al. Postmenopausal Osteoporosis Treatment With Antiresorptives: Effects of Discontinuation or Long-Term Continuation on Bone Turnover and Fracture Risk-A Perspective. JBMR 2017; 27, p. 963-974. Go to original source... Go to PubMed...
    28. Devogelaer JP, Brown JP, Burckhardt P et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int. 2007; 18(9): 1211-1218. Go to original source... Go to PubMed...
    29. Törring O. Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis. Ther Adv Musculoskelet Dis 2015; 7(3): 88-102. Go to original source... Go to PubMed...
    30. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013; 28(8): 1729-1737. Go to original source... Go to PubMed...
    31. Tennis P, Rothman KJ, Bohn RL et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf. 2012; 21(8): 810-817. Go to original source... Go to PubMed...
    32. Khan A, Morrison A, Cheung A, Hashem W, Compston J. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int. 2016; 27(3): 853-859. Go to original source... Go to PubMed...
    33. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80(6 Suppl): 1678S-88S. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.